Eibach E, Voss A C, Junker A
Dtsch Med Wochenschr. 1978 Dec 15;103(50):2003-7. doi: 10.1055/s-0028-1129385.
The five-year survival rate of patients with seminoma (61 cases) of all stages was 81% (seven-year survival rate 67%). Within this group the T1-2N0M0 stage had a five-year survival rate of 100%. Patients with tumours other than seminoma (52 cases) of all stages had a five-year survival rate of 54% (seven-year survival rate 47%). These results and those reported by others are the basis for not advocating routinely total radiation of the lymphatic pathways in the early tumour stages.
所有分期的精原细胞瘤患者(61例)的五年生存率为81%(七年生存率为67%)。在该组中,T1-2N0M0期的五年生存率为100%。所有分期的非精原细胞瘤患者(52例)的五年生存率为54%(七年生存率为47%)。这些结果以及其他研究报告的结果是不主张在肿瘤早期常规对淋巴途径进行全放射治疗的依据。